Dr. Jennifer Chheda has almost 20 years of experience developing, implementing, and managing worldwide patent portfolios covering commercial biologics and pharmaceuticals as well as products in development, including clinical candidates.
Jennifer has been instrumental in the development, implementation, and management of patent portfolios for MedImmune relating to its commercial anti-RSV F antibody; patent portfolios for Icahn School of Medicine at Mount Sinai relating to influenza virus vaccines and chimeric Newcastle Disease Viruses in development; and patent portfolios for AC Immune S.A. and Genentech relating to anti-beta amyloid antibodies, including Genentech's clinical candidate. Jennifer has worked with pioneers developing a universal influenza virus vaccine as well as virus-based cancer therapy. In addition, she was instrumental in developing and managing global patent portfolios for Admune Therapeutics relating to its IL-15/IL-15 receptor alpha clinical trial product, which formed the basis for the acquisition of Admune by Novartis Institutes for BioMedical Research. Furthermore, she has evaluated patent portfolios and prosecuted patent applications relating to, inter alia, enzyme replacement therapy, RNA therapeutics (e.g., miRNA), gene therapy, antibodies, antibody drug conjugates, and cell-based therapies (e.g., CAR-T cells).
Jennifer's experience also includes patentability, invalidity, noninfringement, and freedom-to-operate analyses; conducting due diligences for clients, including potential investors, acquirers, and licensees, such as venture capital firms, biotechnology companies, and pharmaceutical companies; inventorship analysis; and post-grant proceedings, such as inter partes review, interferences, reexaminations, and oppositions.
Jennifer also has experience drafting and negotiating intellectual property agreements, including licensing, sponsored research, and development agreements. In addition, she has patent litigation experience, including drafting expert reports, preparing experts for trial, and drafting legal arguments for briefs.
Patent Prosecutors Beware: Earlier Publication Anticipates Broad Claims of Continuing Application, PTAB Litigation Blog
- April 9, 2016PharmaDJ Roundtable Discussion on Biosimilar and Antibody Development: Options for Asian Biosimilar Companies in the U.S.
- October 28, 2010The Advent of Biosimilars: What you (and your clients) should know
- New York Law School (J.D. 2002); New York University (Ph.D. in Microbiology 1999; M.Sc. in Microbiology 1994); University of Connecticut (B.S. in Molecular and Cellular Biology cum laude 1992)
- New York and registered to practice before the United States Patent and Trademark Office